Neuroimaging and other biomarkers for Alzheimer's disease

The changing landscape of early detection

Shannon L. Risacher, Andrew Saykin

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Next, we evaluate findings from these biomarkers in preclinical and prodromal stages of AD including mild cognitive impairment (MCI) and pre-MCI conditions conferring elevated risk. We then discuss related findings in patients with dominantly inherited AD. We conclude with a discussion of the current theoretical framework for the role of biomarkers in AD and emergent directions for AD biomarker research.

Original languageEnglish
Pages (from-to)621-648
Number of pages28
JournalAnnual Review of Clinical Psychology
Volume9
DOIs
StatePublished - Mar 2013

Fingerprint

Neuroimaging
Alzheimer Disease
Biomarkers
Magnetic Resonance Imaging
Prodromal Symptoms
Cerebrospinal Fluid Proteins
Diffusion Tensor Imaging
Amyloid
Positron-Emission Tomography
Cerebrospinal Fluid
Magnetic Resonance Spectroscopy
Perfusion
Research
Cognitive Dysfunction

Keywords

  • cerebrospinal fluid (CSF)
  • functional MRI (fMRI)
  • genetics
  • magnetic resonance imaging (MRI)
  • mild cognitive impairment (MCI)
  • positron emission tomography (PET)
  • preclinical Alzheimer's disease (AD)

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Neuroimaging and other biomarkers for Alzheimer's disease : The changing landscape of early detection. / Risacher, Shannon L.; Saykin, Andrew.

In: Annual Review of Clinical Psychology, Vol. 9, 03.2013, p. 621-648.

Research output: Contribution to journalArticle

@article{a4d31d120afc46b6b3a3ec7871985806,
title = "Neuroimaging and other biomarkers for Alzheimer's disease: The changing landscape of early detection",
abstract = "The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Next, we evaluate findings from these biomarkers in preclinical and prodromal stages of AD including mild cognitive impairment (MCI) and pre-MCI conditions conferring elevated risk. We then discuss related findings in patients with dominantly inherited AD. We conclude with a discussion of the current theoretical framework for the role of biomarkers in AD and emergent directions for AD biomarker research.",
keywords = "cerebrospinal fluid (CSF), functional MRI (fMRI), genetics, magnetic resonance imaging (MRI), mild cognitive impairment (MCI), positron emission tomography (PET), preclinical Alzheimer's disease (AD)",
author = "Risacher, {Shannon L.} and Andrew Saykin",
year = "2013",
month = "3",
doi = "10.1146/annurev-clinpsy-050212-185535",
language = "English",
volume = "9",
pages = "621--648",
journal = "Annual Review of Clinical Psychology",
issn = "1548-5943",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Neuroimaging and other biomarkers for Alzheimer's disease

T2 - The changing landscape of early detection

AU - Risacher, Shannon L.

AU - Saykin, Andrew

PY - 2013/3

Y1 - 2013/3

N2 - The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Next, we evaluate findings from these biomarkers in preclinical and prodromal stages of AD including mild cognitive impairment (MCI) and pre-MCI conditions conferring elevated risk. We then discuss related findings in patients with dominantly inherited AD. We conclude with a discussion of the current theoretical framework for the role of biomarkers in AD and emergent directions for AD biomarker research.

AB - The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Next, we evaluate findings from these biomarkers in preclinical and prodromal stages of AD including mild cognitive impairment (MCI) and pre-MCI conditions conferring elevated risk. We then discuss related findings in patients with dominantly inherited AD. We conclude with a discussion of the current theoretical framework for the role of biomarkers in AD and emergent directions for AD biomarker research.

KW - cerebrospinal fluid (CSF)

KW - functional MRI (fMRI)

KW - genetics

KW - magnetic resonance imaging (MRI)

KW - mild cognitive impairment (MCI)

KW - positron emission tomography (PET)

KW - preclinical Alzheimer's disease (AD)

UR - http://www.scopus.com/inward/record.url?scp=84875903418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875903418&partnerID=8YFLogxK

U2 - 10.1146/annurev-clinpsy-050212-185535

DO - 10.1146/annurev-clinpsy-050212-185535

M3 - Article

VL - 9

SP - 621

EP - 648

JO - Annual Review of Clinical Psychology

JF - Annual Review of Clinical Psychology

SN - 1548-5943

ER -